

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



PO2

Day/01

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 9/20		A1	(11) International Publication Number: WO 94/15588 (43) International Publication Date: 21 July 1994 (21.07.94)
(21) International Application Number: PCT/FI93/00575 (22) International Filing Date: 31 December 1993 (31.12.93) (30) Priority Data: 9227166.7 31 December 1992 (31.12.92) GB		(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(71)(72) Applicants and Inventors: TÖRMÄLÄ, Pertti, Olavi [FI/FI]; Runeberginkatu 3 A, FIN-33710 Tampere (FI). MIETTINEN-LÄHDE, Saila, Susanna [FI/FI]; Kirsikatu 27 C, FIN-33710 Tampere (FI). (74) Agent: ORION CORPORATION; Orion-Farmos Pharmaceuticals, Patent Department, P.O. Box 65, FIN-02101 Espoo (FI).			

(54) Title: A METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS THROUGH ULTRASONIC MEANS

(57) Abstract

An ultrasonic processing method by which polymer/drug composites can be quickly and efficiently molded to form matrix-type drug delivery systems is disclosed. The advantages of the method include speed and good control of the process. It also causes less degradation in polymers and/or drugs than most conventional processing methods.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS THROUGH ULTRASONIC MEANS

The present invention relates to a method for preparing pharmaceutical compositions using ultrasonic processing.

Matrix-type drug delivery systems, which are capable of releasing pharmaceuticals in a controlled fashion over extended periods of time are well known. Drug releasing matrices have previously been prepared by conventional polymer processing techniques, such as injection molding, extrusion or compression molding. These techniques often lead to noticeable decomposition of the active agent and/or the polymer, or are slow and cumbersome to use. The factors mainly responsible for their degradative effects are long heating times combined with mechanical stress caused by screws or other mixing devices in the machinery. The problems created by heat can be avoided by solvent casting, but this method may result in harmful solvent residues, and it is not suitable for insoluble polymers, such as polyglycolic acid (PGA).

It is an object of the present invention to provide a method for preparing drug releasing compositions eliminating the disadvantages discussed above. The object is realized by a method for preparing a drug releasing biodegradable composition comprising biodegradable polymer matrix and at least one pharmaceutical substance mixed and/or dissolved within said matrix, characterized in that using ultrasonic means a mixture of the biodegradable polymer and the pharmaceutical substance is at least partial melted.

Ultrasonic techniques are widely used in industry for the joining of thermoplastic moldings, e.g. in car and textile industry. It has now been found that ultrasonic processing can successfully be used to plasticize and mold polymeric drug delivery systems. Compared to the previously utilized methods, ultrasonic molding offers the advantage of being faster, more controllable, and substantially less destructive to the polymer and the drug.

Ultrasonic molding is based on a process in which energy from the main supply is converted by a generator into electrical vibrations in the US range (usually 20 kHz), and further transduced into mechanical vibrations of the same frequency. These mechanical vibrations are transmitted to the work pieces through a booster (transformer) and a sonotrode. The heating in the materials to be molded or joined takes place as a result of the absorption and

reflection of the mechanical vibrations in the material and the interface friction of the fragments or joining surfaces.

The time required for ultrasonic processing is always very short, probably less than 1.5 s. This fact is influential in all 5 applications, particularly when mass-produced articles are in question. Short heating times are especially important in drug release applications, in which neither the polymer nor the active agent can withstand elevated temperatures for long periods of time.

10 Ultrasonic molding of polymer/drug composites is accomplished by standard ultrasonic welding equipment, provided it is supplied with a sonotrode and a mold suitable for producing of matrices of desired size and geometry. Tablet- or rod-shaped 15 matrices, for example, are easily produced, but more complicated geometries can also be prepared.

Polymeric materials suitable for ultrasonically processed drug releasing matrices include e.g. polyorthoesters and biodegradable poly- α -hydroxy acids, such as polyglycolide (PGA), polylactides (PLA), polyhydroxybutyrate (PHB) and PHB/polyhydroxy-20 valerate (PHV) copolymers. Many of these materials are extremely difficult to injection mold or extrude due to their narrow melting temperature ranges. The process may, in fact, become impossible to control when the polymers have been blended with pharmaceuticals: drastic changes in the viscosity of the materials can occur 25 within a 0.5 °C change in temperature or with time, and differences in the melting points of the constituents often result in one or more of the substances being at least partially destroyed. In ultrasonic molding these problems can largely be avoided, because the process is almost instantaneous, and because the process parameters (welding time, holding time, pressure, welding energy, welding distance, amplitude, impact speed) can be very accurately 30 determined.

Examples of the drugs compatible with ultrasonic processing 35 are e.g. antibiotics, polypeptides and steroid hormones. Many other classes of pharmaceuticals, the long term and/or local delivery of which is beneficial, can also be used.

Ultrasonically produced drug delivery systems can best be used as macroscopic implantable devices, such as long-term 40 contraceptive systems placed under the skin, or as antibiotic loaded rods implanted in osteomyelitic bone. The preparation of these or other types of implants consists, in general, of mixing the

polymer with the pharmaceutical substances, vacuum drying the blend, and molding it with ultrasound.

Homogenization of the polymer/drug blend can be done for example by mechanically mixing finely ground powders, by stirring 5 the polymer powder in a drug solution, by dissolving both (all) substances in a common solvent, or by impregnating the polymer with the drug solution. Thorough vacuum drying of the materials after blending is preferred for predictable processing and release results.

10 Molding of the materials can be done with a standard ultrasonic welding apparatus, which is equipped with an appropriately designed sonotrode and a mold of desired size and shape. The dried substances are placed into the mold, and ultrasound is applied on them. The processing time required to plasticise and form a 0.25 g 15 sample varies between 0.1 and 1.0 s depending on the materials in question, as well as on the pressure and amplitude (booster) used. The energies transmitted to this size of samples are approximately 50 - 500 Ws.

20 It has been found that most injection molded and extruded matrices show substantially worse and less predictable in vitro release behavior than ultrasonically prepared samples, which is due to the degradative effect of these methods on the polymers and especially to the drugs. In vitro drug release from ultrasonically 25 molded samples is roughly equivalent to that from compression molded samples. However, variation of the results is greater in compression molded samples, and when comparing the processing techniques themselves, ultrasonic molding comes out as the easier, faster and more accurate technique.

30 The invention is further illustrated by the following Examples, where reference is made to the accompanying drawings. In the drawings,

Fig. 1 shows in vitro release of levonorgestrel from ultrasonically processed PLLA matrice,

35 Fig. 2 shows in vitro levonorgestrel release from compression molded PLLA matrice,

Fig. 3 shows in vitro ciprofloxacin release from ultrasonically molded PGA matrice,

Fig. 4 shows cumulative in vitro ciprofloxacin release from ultrasonically molded PGA matrice,

Fig. 5 shows in vitro ciprofloxacin release from compression molded PGA rods,

Fig. 6 shows cumulative in vitro ciprofloxacin release from compression molded PGA rods,

5 Fig. 7 shows in vitro 17- β -estradiol release from ultrasonically molded PHB/PHV slabs (7.5 wt% 17- β -estradiol) and

Fig. 8 shows in vitro 17- β -estradiol release from ultrasonically molded PHB/PHV slabs (15wt% 17- β -estradiol) .

10 EXAMPLE 1.

Effects of injection molding and ultrasonic processing on poly-L-lactide (PLLA)

15 PLLA (MW 260 000) was first dried in vacuum and subsequently either ultrasonically processed or injection molded in nitrogen atmosphere. The samples produced by ultrasound were ø 11 x 2 mm buttons, and the duration of ultrasound application on each sample was approximately 0.3 s. The energy transmitted to the buttons was 200 Ws, and the pressure during molding 1.3 bar. Injection molding was done with a Battenfeld BA 230 apparatus, 20 and the molded samples were shaped as rods of various sizes. Both types of samples were ground and again vacuum dried before testing.

25 Processing-induced changes in polymer properties and structure were assessed by melt flow index (MFI) measurements and differential scanning calorimetry (DSC). The MFI measurements, done at 180 - 195 °C, showed that injection molding had had a major degradative effect on PLLA, as the MFI at all temperatures had markedly increased. The increase in MFI caused by ultrasonic processing was less severe (Table 1). DCS scans showed a 30 slight decrease in melting points in the injection molded as well as in the ultrasonically processed samples. The smaller degree of crystallinity of the ultrasonically prepared PLLA is caused by the quick cooling that follows the ultrasound application (Table 2).

Table 1. Melt flow index (MFI) values of PLLA

	MFI (g/10 min)			
	180°C	185°C	190°C	195°C
Raw material (MW 260000)	-	0.20	0.84	1.25
Injection molded	3.11	5.66	7.60	9.74
Ultrasonically molded	-	4.31	4.30	6.18

Table 2. Melting points (°C) and degrees of crystallinity of PLLA

5

	T _m (deg. C)	Crystallinity (%)
Raw material (MW260000)	185.7	63.4
Injection molded	181.8	61.2
Ultrasonically molded	181.1	38.9

degree of crystallinity calculated from the melting enthalpy of the sample relative to that of 100% crystalline PLLA

10

EXAMPLE 2.

Total concentration of active agents in ultrasonically processed, compression molded and injection molded matrices

15 Ultrasonically molded samples were prepared from vacuum dried PLLA (MW 260 000)/15 wt% levonorgestrel mixture using Rinco PCS ultrasonic welding equipment. The ø 11 x 2 mm, button shaped samples were made using a welding time of 0.3 s, 1.3 bar and appr. 200 Ws of energy per sample. A few of the prepared samples were dissolved in chloroform, and the total concentration levonorgestrel in the solution was determined UV-spectrophotometrically at 240 nm. The levonorgestrel content of the samples was found to be close to 100% of the theoretical amount of the drug present.

25 A similar PLLA/15 wt% levonorgestrel mixture was compression molded into ø 20 x 2 mm slabs at 170 - 175 °C for 5 min. The pressure applied on the samples during processing was 10 MPa. The levonorgestrel content measured from dissolved slabs was again nearly 100% of the expected.

30 Injection molded PLLA/15 wt% levonorgestrel samples were prepared by first melt homogenizing the dried material in a Brabender Plasticord batch mixer at 190 °C, and by then injection molding it into ø 20 x 2 mm slabs with a laboratory scale SP-2

apparatus at 195 - 200 °C. In these samples, only appr. 24 % of the theoretical amount of levonorgestrel was found to be present after processing, which clearly shows the detrimental effect of injection molding / melt homogenization on these materials.

5

EXAMPLE 3.

In vitro release of levonorgestrel from ultrasonically processed, compression molded and injection molded PLLA matrices

10 The in vitro hydrolysis experiments of all samples were done in phosphate buffer (pH 7.4) at 37 °C. The buffer solutions were changes periodically, and the levonorgestrel concentration in the solutions was assessed by HPLC (Merck Hitachi).

15 The compression molded PLLA/15% levonorgestrel matrices have released levonorgestrel fairly steadily, 10-12 µg/day, after initial burst (Fig. 2). The release has been strongly dependent on the solubility of the steroid in the buffer solution rather than on the properties of the matrix. No signs of the active agent having been destroyed during processing have been detected, however.

20 The release from ultrasonically processed samples (Fig. 1) has been 6-8 µg/day, after the initial burst (after about 25 days). After 180 days the total amount released has been 4.8 %.

25 Levonorgestrel release from the injection molded samples was barely at a detectable level (<<1 µg/day) throughout most of the test period. Because of the very scant release, and also due to rapidly degrading matrices, the experiments were deemed unsuccessful and discontinued after two months of hydrolysis.

EXAMPLE 4.

30 In vitro ciprofloxacin release from ultrasonically processed and compression molded polyglycolic acid (PGA) matrices.

35 Ciprofloxacin loaded PGA matrices, which can be used for the local, controlled antibiotic treatment of osteomyelitis, were prepared from ciprofloxacin impregnated Dexon 2"S" suture. The impregnated (5 wt% ciprofloxacin), vacuum dried suture was either compression molded into ø 3.2 x 5 mm rods or ultrasonically formed into ø 11 x 2 mm slabs. The compression molding was done at 200 - 205 °C under 0 - 20 MPa pressure for 6 - 7 minutes. Ultrasonic processing was accomplished with a welding time of

appr. 1.5 s, 1.2 bar pressure and 270 - 300 Ws of transmitted energy.

5 Ciprofloxacin release from the ultrasonically prepared samples started at $1849 \pm 93 \mu\text{g/day}$ ($X \pm \text{SD}$, $N=8$) and tapered down to $0.8 \pm 0.3 \mu\text{g/day}$ after 112 days (Fig. 3). The experiment was discontinued at this time, because all of the samples had degraded completely. At the completion of the hydrolysis the percentage of the antibiotic release had reached $55 \pm 5 \%$ of its theoretical amount (Fig. 4). The remaining appr. 45 % had been lost during processing due to incomplete absorption into the sutures.

10 Hydrolysis results of the compression molded samples are presented in Figures 5 and 6. It can be seen that the ciprofloxacin release from the samples was comparable to that from ultrasonically processed samples, especially considering the differences in 15 the size and shape of the samples. However, variation between individual samples was noticeably greater in the compression molded rods. Also, the compression molding process takes 20-30 min/sample, whereas the ultrasonic forming can be done in less than two seconds.

20

EXAMPLE 5.

Ultrasonically molded PHB/PHV / 17- β -estradiol samples

25 Micronized estradiol and PHB/PHV powder (particle size < 350 μm) were mechanically mixed in the ratios of 7.5 : 92.5 and 15 : 85. The homogenized mixture was vacuum dried at 30 °C for 3 days and then ultrasonically molded into $\varnothing 11 \times 2$ mm slabs. The processing parameters included the welding time of 0.118 - 0.128 s, 5.0 s holding time, 1.1 bar pressure and 53 Ws of welding energy. Some of the slabs were dissolved in chloroform, and the total 30 estradiol content of the samples was determined from the solution by a Perkin Elmer Lambda 17 UV/VIS-Spectrophotometer at 280 nm. The amount of estradiol found was close to 100 % of the theoretical.

35 In vitro hydrolysis experiments of PHB/PHV / 17- β -estradiol slabs were done in phosphate buffer (pH 7.4, 37 °C). The buffer solution was periodically changed, and the estradiol concentration in the solution was assessed by HPLC (Merck Hitachi). The results show a nearly first order release, which is typical for matrix-type drug delivery systems (Fig. 7 and 8).

40 Fig. 7 (mixing ratio 7.5 : 92.5) shows that the release has been 6-11 $\mu\text{g/day}$ during the period of 20-70 days, after the initial

burst. During the period of 120-290 days the release has been about 2-4 μ g/day. After 290 days the total amount released has been 11.5 %.

Fig. 8 (mixing ratio 15 : 85) shows that the release has been

5 10-13 μ g/day during the period of 50-100 days, after the initial burst. During the period of 100-230 days the release has been about 4.5-10 μ g/day. After 230 days the total amount released has been 10.5 %.

CLAIMS

1. A method for preparing a drug releasing biodegradable composition comprising biodegradable polymer matrix and at least one pharmaceutical substance mixed and/or dissolved within said matrix, characterized in that using ultrasonic means a mixture of the biodegradable polymer and the pharmaceutical substance is at least partial melted.
- 10 2. A method according to Claim 1 characterized in that the mixture of biodegradable polymer and pharmaceutical substance is vacuum dried before the ultrasonical melting.
- 15 3. A method according to any one of Claims 1-2 characterized in that the biodegradable polymer matrix comprises a polyorthoester, a polylactide or a poly- α -hydroxy acid.
4. A method according to Claim 3 characterized in that the biodegradable polymer matrix comprises polyglycolide (PGA), poly-L-lactide (PLLA), polyhydroxybutyrate (PHB) or a PHB/polyhydroxyvalerate (PHV) copolymer.
- 20 5. A method according to any one of Claims 1-4 characterized in that the pharmaceutical substance is an antibiotic, a steroid hormone or a polypeptide.
- 25 6. A method according to Claim 5 characterized in that the pharmaceutical substance is levonorgestrel, ciprofloxacin or 17- β -estradiol.
- 30 7. A drug releasing biodegradable composition comprising biodegradable polymer matrix and at least one pharmaceutical substance mixed and/or dissolved within said matrix characterized in that said composition is prepared according to any one of Claims 1-6.
8. A composition according to Claim 7 characterized in that the composition is capable of being implanted in the human or animal body.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8

INTERNATIONAL SEARCH REPORT

Inte: Application No
PCT/FI 93/00575

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP, A, 0 556 158 (CIBA-GEIGY AG) 18 August 1993	1,5-7
P, Y	see claim 1 see column 4, line 13 - line 35 see column 5, line 37 - line 39 -----	3,4,8
Y	EP, A, 0 406 013 (ETHICON INC.) 2 January 1991 see claims 1,5,7 see column 5, line 26 - line 29 -----	3,4,8

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

1

Date of the actual completion of the international search

2 March 1994

Date of mailing of the international search report

16.03.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 cpo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Ventura Amat, A

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte onal Application No
PCT/FI 93/00575

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0556158	18-08-93	US-A-	5268179	07-12-93
		AU-A-	3291093	19-08-93
		CA-A-	2089468	15-08-93
EP-A-0406013	02-01-91	US-A-	5171148	15-12-92
		CA-A-	2020076	31-12-90
		JP-A-	3068352	25-03-91

THIS PAGE BLANK (USPTO)